Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing
drugs for HIV and Multiple Sclerosis, has announced that its wholly-owned drug
discovery subsidiary, ReceptoPharm, has reported initial positive safety data
from its Phase IIb/IIIa clinical study of RPI-78M for treating
Adrenomyeloneuropathy (AMN). RPI-78M is ReceptoPharm's leading drug candidate
for treating neurological and autoimmune disorders.
"Initial reports and
feedback from physicians involved with this clinical study have reported that
patients have experienced no adverse side effects from RPI-78M," explained Paul
Reid, CEO of ReceptoPharm. "This is an important indicator of the success of
this clinical study, as it provides the medical and pharmacological communities
with early evidence supporting the safety of our leading drug candidate,
RPI-78M," he concluded.
Adrenomyeloneuropathy (AMN) is a rare inherited
metabolic disorder that affects approximately 30,000 people worldwide. The
disorder is characterized by the loss of the fatty covering (myelin sheath) on
nerve fibers within the brain (cerebral demyelination) and the progressive
degeneration of the adrenal gland (adrenal atrophy). Neurological disability in
AMN is slowly progressive over several decades.
AMN interests the wider
neurologic community because of its similarities to Multiple Sclerosis (MS).
There is currently no approved treatment for AMN. Additionally, the disease's
rarity designates it as an orphan drug candidate both in Europe and in the U.S.
The Company has applied for Orphan drug status in the U.S. and intends on doing
so for the EU.
ReceptoPharm expects to present the complete clinical
findings and data from this study by the end of September.About Nutra
Nutra Pharma Corp. is a biopharmaceutical company
specializing in the acquisition, licensing and commercialization of
pharmaceutical products and technologies for the management of neurological
disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp.
through its subsidiaries carries out basic drug discovery research and clinical
development and also seeks strategic licensing partnerships to reduce the risks
associated with the drug development process. The Company's subsidiary,
ReceptoPharm, Inc., is developing these technologies for the production of drugs
for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer
Diagnostics, is engaged in the research and development of diagnostic test kits
designed to be used for the rapid identification of infectious diseases such as
Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma
continues to identify and acquire intellectual property and companies in the
biotechnology arena.SEC Disclaimer
This press release
contains forward-looking statements. The words or phrases "would be," "will
allow," "intends to," "will likely result," "are expected to," "will continue,"
"is anticipated," "estimate," "project," or similar expressions are intended to
identify "forward-looking statements." Actual results could differ materially
from those projected in Nutra Pharma's ("the Company") business plan. The
Company's business is subject to various risks, which are discussed in the
Company's filings with the Securities and Exchange Commission ("SEC"). The
initial safety data from the clinical study in Adrenomyeloneuropathy (AMN)
should not be construed as an indication in any way whatsoever of the value of
the Company or its common stock. The Company's filings may be accessed at the
SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of
this press release and should not be relied upon as of any subsequent date. The
Company cautions readers not to place reliance on such statements. Unless
otherwise required by applicable law, we do not undertake, and we specifically
disclaim any obligation, to update any forward-looking statements to reflect
occurrences, developments, unanticipated events or circumstances after the date
of such statement.http://www.NutraPharma.comhttp://www.ReceptoPharm.com